March 21, 2023
3 min watch
Save
VIDEO: Combo therapy ‘very effective’ in TALAPRO-2 trial
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Shilpa Gupta, MD, Director of the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute, discusses data presented from the TALAPRO-2 trial, presented at ASCO Genitourinary Cancers Symposium.
Gupta goes in-depth on the data from the trial, which studied the combination of poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna, Pfizer) and enzalutamide (Xtandi; Astellas, Pfizer) in an unselected population of patients with metastatic castration-resistant prostate cancer (mCRPC).
“It will remain to be seen what the approval indication is, but it’s very encouraging that this combination was very effective,” Gupta said.
Reference:
- Agarwal N, et al. TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Presented at: ASCO Genitourinary Cancers Symposium, Feb. 16-18, 2023; San Francisco.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Gupta reports consulting for AVEO, EMD Serono, Gilead Sciences, Guardant Health, Loxo/Lilly, Merck and Pfizer.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.